Join KBI Biopharma, Inc. at PepTalk 2023! Be sure to stop by our booth to meet with Aruna Mor, Sr. Vice President, Global Marketing & Head of Business Development (Americas) for KBI Biopharma, Jon Viola, Business Development Manager, Séverine Fagète, Vice President CLD, and Juliette Trepeau, R&D Cell Biology Manager, Selexis SA, . We look forward to seeing you in San Diego!
Scientific Talk: CHO Fed-Batch Strategies To Rapidly Increase mAb Titer By 100% Without Sacrificing Product Quality
Séverine Fagète, Vice President CLD Talk track: Process Intensification Date: January 17th, 11:30am PT
In the field of therapeutic antibody production, diversification of fed-batch strategies is flourishing in response to the market demand. All manufacturing approaches tend to follow the generally accepted dogma of increasing titer since it directly increases manufacturing output. Selexis has changed the parameters which influence titer and developed novel hybrid strategies that reduce timelines without compromising productivity quality.
About KBI Biopharma:
KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 500+ client partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond.
About the Conference:
PepTalk connects protein science researchers from around the globe to share case studies, unpublished data, breakthroughs, and solutions that support and enhance biotherapeutics R&D. This year’s event will feature world-renowned speakers, cutting-edge technologies, and engaging networking events. Programming includes in-depth coverage of antibody discovery, protein engineering, bispecific antibodies, emerging immunotherapies, protein aggregation, machine learning, cell and gene therapy, protein expression, purification and production.